Drugs.com - Clinical Trials

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent...

Mar 15, 2025 - 00:11
 0
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent...
Read More

Tags:

Previous Article

How nGroup & Locus Robotics Boosted Warehouse Productivity by 229%

Next Article

5 Acre Estate In Gastonia, North Carolina (PHOTOS)

Related Posts

ViiV Healthcare’s Investigational Broadly Neutralising Antibody - N6LS - Successfully Maintains Viral Suppression in Long-Acting Treatment of HIV

ViiV Healthcare’s Investigational Broadly Neutralising ...

Mar 13, 2025  0

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Kura Oncology and Kyowa Kirin Announce Positive Ziftome...

Feb 9, 2025  0

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Denali Therapeutics Announces Primary Analysis and Long...

Mar 7, 2025  0